IIEF and SEP3 improved. In ordinary language, what did the men actually get?
A scoreboard, not a league table
Before anyone ranks brands, name the tools. ED trials do not eyeball a bedroom. They use the same questionnaires.
The workhorse is the International Index of Erectile Function, especially the erectile-function domain, IIEF-EF. Men answer items about firmness and reliability. The domain sums to a severity score. Trials also log the Sexual Encounter Profile. SEP2 asks whether penetration happened. SEP3 asks whether the erection lasted long enough to finish. Those three numbers are how the whole class is judged, so vardenafil's package can be laid next to sildenafil and tadalafil without inventing a new yardstick.
In the pivotal placebo-controlled work, vardenafil moved all three. IIEF-EF rose. Successful penetration attempts climbed. More encounters ended with an erection that lasted through intercourse. Effects grew with dose. That is a strong case for the drug as a drug. It is not a case that the drug won a tournament. Mechanism detail stays in the vardenafil medicine file. This page files endpoints, hard groups, and the QT row.
Four fixed-dose trials. 2431 men. Three months.
| North American general ED, 3 months | Placebo | 5 mg | 10 mg | 20 mg |
|---|---|---|---|---|
| SEP2 (penetration) | 52% | 65% | 75% | 80% |
| SEP3 (finished intercourse) | 32% | 51% | 64% | 65% |
The US label's main efficacy package is four double-blind, randomized, placebo-controlled, fixed-dose, parallel, multicenter trials. 2431 men, ages 20 to 83, mean age 57. Two trials in a general ED population. One in diabetes. One after prostatectomy. Doses in those studies were 5, 10, and 20 mg - not 2.5. The 2.5 mg face is a labeled interaction and metabolism rung, not a pivotal efficacy arm. Levitra was taken as needed, without regard to meals, and primary endpoints were read at three months.
Mean baseline IIEF-EF in those trials was 11.8 on a 0-30 scale - moderate-to-severe territory, not a mild-nuisance sample. Vardenafil at 5, 10, and 20 mg improved EF domain, SEP2, and SEP3 versus placebo across age bands and across reported race groups. In the North American general-ED trial, SEP2 at three months was 65% on 5 mg, 75% on 10 mg, and 80% on 20 mg, against 52% on placebo. SEP3 was 51%, 64%, and 65% against 32% on placebo. The European general-ED trial lined up the same way.
Read those percentages as 'more yes answers than placebo,' not as a promise that four out of five nights will be perfect. Placebo already cleared penetration about half the time. The drug's job was the gap, and the gap was real.
The hard files: diabetes and nerve-sparing surgery
Mild ED answers almost any PDE5 tablet. The test is the groups where vessels and nerves are already damaged.
The diabetes trial enrolled 439 men, mean age 57, fixed doses 10 and 20 mg. High glucose injures the small vessels and nerves that drive erection, so every drug in this class returns a smaller absolute effect here. Vardenafil still moved the scoreboard. SEP2: 61% on 10 mg and 64% on 20 mg against 36% on placebo. SEP3: 49% and 54% against 23%. File that as 'works, ceiling lower,' not as a vardenafil flaw. Better glucose control helps any tablet in the class. A smaller gap than a non-diabetic man's is disease burden, not a failed molecule.
The post-prostatectomy trial enrolled 427 men, mean age 60, again 10 and 20 mg. SEP2: 47% and 48% against 22% on placebo. SEP3: 37% and 34% against 10%. Those numbers only make sense if erection nerves were spared. If the nerves are gone, no PDE5 tablet replaces missing wiring. Setting that expectation is part of honest prescribing, not a footnote. How the molecule reached market is in the Wuppertal-to-Levitra origin file. How you time a dose is not this page's job.
Levitra 2.5-5 mg reviews are a ladder, not a ranking
| File | Labeled vardenafil move | Why the rung changes |
|---|---|---|
| Most adults | Start 10 mg ~60 min before sex; 5-20 mg range | Titrate to effect and tolerability |
| Age 65+ | Consider 5 mg start | Higher exposure with age |
| Child-Pugh B liver | Start 5 mg; cap 10 mg | Clearance falls, levels rise |
| Strong CYP3A4 inhibitors | Cap often 2.5 mg (ritonavir: 2.5 mg / 72 h) | AUC can jump many-fold |
| Stable on an alpha-blocker | Lowest labeled start, separated in time | Additive hypotension |
| Max frequency | Once per day | No extra benefit past that |
Film-coated tablets come at 2.5, 5, 10, and 20 mg. Most men work 5-10-20. The label starts most adults at 10 mg about an hour before sex, then moves to 20 or down to 5. Trial dose response is real: 20 beat 10, which beat 5, on the same endpoints. Climbing because a forum said 20 is 'the real dose' is not evidence. Stay at the lowest rung that reliably works.
The ladder bends for named files. Age 65 and over: consider a 5 mg start because Cmax and AUC run about 34% and 52% higher. Moderate hepatic impairment (Child-Pugh B): start 5 mg, do not exceed 10 mg. Strong CYP3A4 inhibitors force steep cuts - down to 2.5 mg, and with ritonavir no more than 2.5 mg in 72 hours. Alpha-blockers need a low, time-separated start so two blood-pressure drops do not stack. None of that is optional fine print. It is how a proven tablet stays a proven tablet.
The QT row: 59 men, 10 mg, 80 mg, moxifloxacin
If one labeled fact separates vardenafil from its siblings, it is electrical timing on the tracing - not bench potency.
A single-dose, double-blind, randomized, placebo- and active-controlled crossover study put vardenafil in 59 healthy men aged 45-60. Therapeutic 10 mg film-coated and supratherapeutic 80 mg (four times the highest recommended dose) were compared with moxifloxacin 400 mg, the usual positive control because it lengthens QT. The tracing was read at one hour, near typical peak. Therapeutic and supratherapeutic vardenafil and moxifloxacin produced similar QTc increases. The study was not built for a statistical bake-off between drugs or doses. The clinical meaning of those milliseconds is still called unknown on the label.
Heart rate rose a little - about 5 beats per minute after 10 mg, about 6 after 80 mg. The 80 mg arm was chosen because it covers concentrations seen when a low 5 mg dose sits with ritonavir 600 mg twice daily, the ugliest CYP3A4 pile-up in the interaction table. That is why a 2.5 mg cap exists on ritonavir. The QT row and the interaction row are the same pile of exposure.
Additive minutes: the gatifloxacin add-on
| Feature | Vardenafil on the evidence | Against the class |
|---|---|---|
| IIEF-EF, SEP2, SEP3 | Strong, dose-dependent vs placebo | Comparable to sildenafil and tadalafil |
| In-vitro potency | Holds PDE5 at lower concentration | Does not translate to a better night |
| Onset / duration | About 30-60 min / about 4-5 h | Sildenafil-like window, not tadalafil's ~36 h |
| QT interval | Modest labeled prolongation; additive with another QT drug | Clearest QT row in the class |
| Who walks away | Congenital long QT; Class IA / III antiarrhythmics | Siblings lack this veto |
| Nitrates | Absolute contraindication | Same veto for the whole class |
A separate postmarketing study in 44 healthy volunteers gave 10 mg Levitra alone, gatifloxacin 400 mg alone, and both together. Placebo-subtracted QTcF change: about 5 msec for vardenafil (90% CI 2-8), about 4 msec for gatifloxacin (90% CI 1-7), about 9 msec when stacked (90% CI 6-11). Additive. Not synergistic magic. Still a reason the label tells you to think before you stack two QT-active drugs.
For a healthy man with a normal heart, this is a labeled caution, not a practical scare. It becomes a decision in two stamped situations: congenital long-QT syndrome - avoid vardenafil - and men on Class IA antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol). In those files I pick another PDE5 inhibitor. Sildenafil and tadalafil do not carry this signal to the same degree. That is the fingerprint. It should move prescriptions more than any 'more potent' slide ever should. Clock and food, which can change peak and therefore the hour you care about, sit in the timing, fat, and grapefruit card.
What the evidence does not crown
Three drugs, one mechanism, three personalities. Sildenafil is the original with a food quirk - see the sildenafil medicine file. Tadalafil is long-acting and untethers the weekend - see the tadalafil medicine file. Vardenafil is the shorter middle option with the QT caveat. Efficacy is a near-tie. Duration, food, cost, and the QT row decide choices. Want spontaneity across two days? Tadalafil's duration usually wins. On-demand need and a normal tracing? Any of the three can fit. Long QT or a Class IA / III drug? Step off vardenafil.
Summed up: vardenafil is well proven and easy to oversell. It improves erectile function on validated endpoints, climbs a clean 5-to-20 mg ladder, and holds up in diabetes and after nerve-sparing surgery. Lab potency is talk. The decision-grade fact is the QT row. Underneath sits the nitrate contraindication for the entire class - unchanged, non-negotiable. How the molecule reached the stamp is in the Wuppertal origin file. How you swallow it without a greasy plate ruining the peak is in the timing card.
Reader mail
Reader questions on this article
Answered by Dr. Priya Anand, MD · Urology & men's health
The evidence page drew ranking questions. We opened the endpoints, struck the league table, and filed the QT row.
IIEF-EF is a questionnaire about how firm and reliable erections are. It rose on vardenafil versus placebo. SEP3 is the diary item that matches real life: did the erection last long enough to finish intercourse? In the North American general-ED trial, yes-answers at three months were 51% on 5 mg, 64% on 10 mg, and 65% on 20 mg, against 32% on placebo. SEP2 is penetration only - necessary, not the same as a finished encounter. Vardenafil moved both. Translation: more men completed sex more often. That is a scoreboard. It is not a promise of every night, and it is not a ranking against Viagra or Cialis.
I have diabetes. Is there any point, or do these tablets bounce off me?
There is a point, and the diabetes trial is why I can say that without guessing. 439 men. 10 and 20 mg. SEP2 61% and 64% against 36% placebo. SEP3 49% and 54% against 23%. Diabetes damages the vessels and nerves that drive erection, so your ceiling may sit lower than a man without diabetes. Lower is not zero. Better glucose control helps the tablet. Do not read a smaller effect as drug failure. Read it as disease burden. Titrate with a clinician. MedlinePlus vardenafil is a plain public page if you want the same INN in consumer language.
I had a prostatectomy. Will vardenafil bring things back?
Almost entirely a nerve question. Nerve-sparing operation with intact wiring? The 427-man trial showed benefit - SEP3 37% on 10 mg and 34% on 20 mg against 10% on placebo. Nerves removed or badly damaged? No PDE5 tablet replaces missing cables. That is anatomy, not vardenafil failing. Injections and devices work by other routes. First step: know exactly what surgery preserved. Then set the expectation with your urologist before anyone chases 20 mg as if milligrams could grow a nerve.
You keep saying more potent but not better. That still sounds like a contradiction.
Split the files. Potency here means vardenafil blocks PDE5 at a lower concentration than sildenafil in a dish. True. Measurable. Erections do not get firmer past sufficient blockade. Once cyclic GMP can build, extra grip is a dimmer already at full brightness. Trial response rates across the three drugs are broadly similar. I weigh those, plus duration and the QT row, when I choose. I do not weigh an IC50 slide. If a rep still leads with 'more potent,' strike it and ask for SEP3.
I take amiodarone. Does the QT row rule Levitra out for me?
For you, I would avoid vardenafil and pick another PDE5 inhibitor. Amiodarone is Class III. Both it and vardenafil can lengthen QT. The 44-volunteer add-on study with gatifloxacin showed the minutes stack - about 5 msec and 4 msec alone, about 9 msec together. The label tells you to avoid Class IA and Class III drugs and congenital long QT. Sildenafil or tadalafil lack this veto. Bigger rule still: any nitrate for chest pain bans the whole class. Bring the full list to whoever prescribes and confirm with your cardiologist. The QT wording is on the Levitra DailyMed label.
Between sildenafil, tadalafil, and vardenafil, how do you actually pick if efficacy is a tie?
Two questions beat a ranking. First: how do you want to time sex? Weekend spontaneity? Tadalafil's long duration is hard to beat - see the tadalafil medicine file. Happy planning around an on-demand pill? Sildenafil or vardenafil both fit. Second: heart file? Long QT or those rhythm drugs? Steer off vardenafil. Beyond that: cost, food, and trial-and-error. Some men simply answer one tablet better. No universal best. A best for you. The hour and the greasy plate that ruin a vardenafil peak are on the timing card.
Is 20 mg worth it, or should I stay at 10? The reviews online all shout the top dose.
Stay at the lowest dose that reliably works. Climb only if it does not. Trials show dose response - 20 mg beat 10 on averages. Average is not you. Higher rungs bring more headache, flushing, stuffy nose, and a larger QT effect. Start 10 mg for most adults, give it a fair try with timing right, move to 20 only if 10 fails. Some men settle at 5. Some interaction files never leave 2.5. Climb by response, not by a forum. Absolutes unchanged: no nitrates, once daily max. Mayo Clinic's vardenafil page stays level-headed on that ladder.
Why does this review keep saying 2.5-5 mg when the big trials used 5, 10, and 20?
Because this desk's SERP lock is the labeled low rungs, and because 2.5 mg is where the interaction file actually lives. The pivotal efficacy arms were 5, 10, and 20. The 2.5 mg face is for ritonavir, other strong CYP3A4 inhibitors, and the cautious start next to an alpha-blocker. Age 65+ and Child-Pugh B start at 5. If a review only shouts 20 mg, it is selling a rung, not reading the package. I file 2.5-5 mg reviews as 'who must start small,' not as '5 mg beat the class.'
If I only keep one line from this evidence page, what is it?
Keep this: the tablet works on IIEF and SEP, including in diabetes and after nerve-sparing surgery. It does not win a ranking. The QT row is the split - congenital long QT or Class IA / III drugs, pick a sibling. Nitrates remain a class veto. Then take the med list to a clinician who has examined you. This is a teaching line. It is not a prescription. The origin dates are in the Wuppertal file. The molecule itself is in the vardenafil medicine file.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated